ERBB2 and neoplasm: Non-negative matrix factorization (see Materials and Methods) was used to compare samples on the basis of parity, tumour phenotype and Erbb2/Neu locus amplification status (by genomic qPCR) and to determine which of these comparisons generated the most distinct and stable sample clusters, i.e. which was the strongest driver of differences in gene expression pattern.